clonoSEQ, from Adaptive Biotechnologies, can detect 1 cancer cell among a million healthy cells. Adaptive Biotechnologies received its third approval from the FDA for the use of its next-generation ...
This systematic review focusing on the targeted therapy era found solid associations between measurable residual disease (MRD) and clinical outcomes in patients with chronic lymphocytic leukemia.
Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...
Menlo Park (pte003/02.12.2019/06:05) Betrug mit Kryptowährungen wie Bitcoin hat unzählige Opfer in den ersten neun Monaten des Jahres 2019 bereits 4,4 Mrd. Dollar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results